A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.

Trial Profile

A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs PSN 010 (Primary) ; Glibenclamide
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Sep 2010 Planned end date changed from 1 Mar 2011 to 1 Jun 2010 as reported by ClinicalTrials.gov.
    • 25 Jun 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top